A ß-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration

Identifying which among several in cellulo pharmacological activities is necessary for the proper in vivo activity is essential for further drug development against Alzheimer's disease pathophysiological processes. An in-depth structure-activity relationship-based study has been carried out, an...

Full description

Saved in:
Bibliographic Details
Main Authors: Marie Tautou (Author), Sabiha Eddarkaoui (Author), Florian Descamps (Author), Paul-Emmanuel Larchanché (Author), Jamal El Bakali (Author), Liesel Mary Goveas (Author), Mélanie Dumoulin (Author), Chloé Lamarre (Author), David Blum (Author), Luc Buée (Author), Patricia Melnyk (Author), Nicolas Sergeant (Author)
Format: Book
Published: Frontiers Media S.A., 2021-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8935d38d81d34dc79eee67e56e27fe2a
042 |a dc 
100 1 0 |a Marie Tautou  |e author 
700 1 0 |a Sabiha Eddarkaoui  |e author 
700 1 0 |a Sabiha Eddarkaoui  |e author 
700 1 0 |a Florian Descamps  |e author 
700 1 0 |a Paul-Emmanuel Larchanché  |e author 
700 1 0 |a Jamal El Bakali  |e author 
700 1 0 |a Liesel Mary Goveas  |e author 
700 1 0 |a Mélanie Dumoulin  |e author 
700 1 0 |a Chloé Lamarre  |e author 
700 1 0 |a David Blum  |e author 
700 1 0 |a David Blum  |e author 
700 1 0 |a Luc Buée  |e author 
700 1 0 |a Luc Buée  |e author 
700 1 0 |a Patricia Melnyk  |e author 
700 1 0 |a Nicolas Sergeant  |e author 
700 1 0 |a Nicolas Sergeant  |e author 
245 0 0 |a A ß-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration 
260 |b Frontiers Media S.A.,   |c 2021-06-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2021.679335 
520 |a Identifying which among several in cellulo pharmacological activities is necessary for the proper in vivo activity is essential for further drug development against Alzheimer's disease pathophysiological processes. An in-depth structure-activity relationship-based study has been carried out, and two molecules, named MAGS02-14 and PEL24-199, that share a ß-secretase modulatory effect associated or not to a lysosomotropic activity in cellulo have been identified. In terms of chemical formulas, MAGS02-14 and PEL24-199 only differ from each other by a single nitrogen atom. The study aimed to elucidate the in vivo pharmacological effects of lysosomotropic and/or the ß-secretase modulatory activity in a tau pathology mouse model. To address this question, the THY-Tau22 transgenic model of tauopathy was treated with both compounds for 6 weeks in a curative paradigm. Short-term memory, tau burden, and inflammatory processes were analyzed using orthogonal methods, and PEL24-199, but not MAGS02-14, was shown to restore the short-term memory and reduce the neurofibrillary degenerating process. These effects were associated with a reduced phosphorylation of tau, an increased phosphatase expression, and decreased astrogliosis. Our results, therefore, suggest that the lysosomotropic activity may be nonessential for the effect on tau pathology. 
546 |a EN 
690 |a Alzheimer's disease 
690 |a BACE protein 
690 |a lysosomes 
690 |a proteostasis 
690 |a tauopathy 
690 |a tau pathology 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 12 (2021) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2021.679335/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/8935d38d81d34dc79eee67e56e27fe2a  |z Connect to this object online.